Graphene oxide nanoscaffold functionalized with adipose-derived mesenchymal stem cells and sildenafil promotes urethral stricture repair and tissue regeneration.
Durán M., Camargo GCA., Oliveira G., Alonso JCC., Alves PCM., Volpe BB.
Animal Study, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Tissue Cell (2025)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41043313
- DOI
- 10.1016/j.tice.2025.103171
Abstract (original English)
Urethral stricture is a common and challenging urological disorder marked by fibrotic narrowing of the urethral lumen, which leads to urinary obstruction and diminished quality of life. Current surgical options are associated with high recurrence rates and limited tissue regeneration. To address these limitations, we developed a multifunctional therapeutic platform integrating a nanostructured graphene oxide scaffold functionalized with polyethylene glycol and poly(ε-caprolactone) (GO/PEG-NH₂/PCL), seeded with human adipose-derived mesenchymal stem cells (ADMSCs) and combined with oral sildenafil. In vitro analyses confirmed scaffold biocompatibility and sustained ADMSC viability, as assessed by fluorescence microscopy, with preservation of spindle-shaped morphology at low GO concentrations. In vivo, we employed a rabbit model of surgically induced urethral stricture and compared four groups: Control, Stricture, Scaffold+ADMSCs, and Scaffold+ADMSCs+Sildenafil. Ten weeks post-treatment, histological and immunohistochemical evaluations revealed that the combinatorial approach significantly restored urethral architecture and lumen patency. This was accompanied by reduced collagen deposition, enhanced smooth muscle organization, and upregulated expression of epithelial differentiation markers (Uroplakin, Desmocollin) and progenitor markers (CD117), alongside downregulation of the f
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.